Total Payments
$88,733
2023 Payments
$11,111
Companies
7
Transactions
109
Payment Breakdown by Category
Other$49,500 (55.8%)
Consulting$25,420 (28.6%)
Travel$9,141 (10.3%)
Food & Beverage$4,672 (5.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,500 | 25 | 55.8% |
| Consulting Fee | $25,420 | 5 | 28.6% |
| Travel and Lodging | $9,141 | 31 | 10.3% |
| Food and Beverage | $4,672 | 48 | 5.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alkermes, Inc. | $84,796 | 88 | $0 (2023) |
| Axsome Therapeutics, Inc. | $2,439 | 2 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $714.81 | 11 | $0 (2019) |
| Neurocrine Biosciences, Inc. | $412.54 | 4 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $236.17 | 2 | $0 (2018) |
| Indivior Inc. | $118.74 | 1 | $0 (2018) |
| Lundbeck LLC | $15.21 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $11,111 | 11 | Alkermes, Inc. ($8,672) |
| 2022 | $53,246 | 60 | Alkermes, Inc. ($53,155) |
| 2021 | $22,908 | 19 | Alkermes, Inc. ($22,783) |
| 2019 | $431.88 | 4 | Janssen Pharmaceuticals, Inc ($310.75) |
| 2018 | $703.49 | 7 | Otsuka America Pharmaceutical, Inc. ($236.17) |
| 2017 | $332.29 | 8 | Janssen Pharmaceuticals, Inc ($243.91) |
All Payment Transactions
109 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/28/2023 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,400.00 | General |
| Category: CNS | ||||||
| 09/22/2023 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Psychology/Psychiatric | ||||||
| 09/12/2023 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Travel and Lodging | In-kind items and services | $190.70 | General |
| Category: CNS | ||||||
| 09/12/2023 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $115.77 | General |
| Category: CNS | ||||||
| 08/01/2023 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $122.52 | General |
| Category: CNS | ||||||
| 07/15/2023 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Travel and Lodging | Cash or cash equivalent | $439.44 | General |
| Category: Psychology/Psychiatric | ||||||
| 06/29/2023 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: CNS | ||||||
| 03/29/2023 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: CNS | ||||||
| 03/09/2023 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $73.52 | General |
| Category: CNS | ||||||
| 02/22/2023 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $115.65 | General |
| Category: CNS | ||||||
| 02/21/2023 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $103.39 | General |
| Category: CNS | ||||||
| 11/10/2022 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: CNS | ||||||
| 09/19/2022 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: CNS | ||||||
| 09/16/2022 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $13.56 | General |
| Category: CNS | ||||||
| 08/22/2022 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA INITIO | Food and Beverage | In-kind items and services | $109.50 | General |
| Category: CNS | ||||||
| 07/22/2022 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: CNS | ||||||
| 07/12/2022 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Consulting Fee | Cash or cash equivalent | $4,750.00 | General |
| Category: CNS | ||||||
| 07/12/2022 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: CNS | ||||||
| 07/12/2022 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Travel and Lodging | In-kind items and services | $957.20 | General |
| Category: CNS | ||||||
| 07/12/2022 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Travel and Lodging | In-kind items and services | $468.29 | General |
| Category: CNS | ||||||
| 07/12/2022 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $110.21 | General |
| Category: CNS | ||||||
| 07/12/2022 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Travel and Lodging | In-kind items and services | $93.27 | General |
| Category: CNS | ||||||
| 07/12/2022 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Travel and Lodging | In-kind items and services | $40.00 | General |
| Category: CNS | ||||||
| 07/12/2022 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Travel and Lodging | In-kind items and services | $19.79 | General |
| Category: CNS | ||||||
| 06/28/2022 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $99.67 | General |
| Category: CNS | ||||||
About Dr. Richard Nockowitz, M.D
Dr. Richard Nockowitz, M.D is a Addiction Medicine healthcare provider based in Lima, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1245228717.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Nockowitz, M.D has received a total of $88,733 in payments from pharmaceutical and medical device companies, with $11,111 received in 2023. These payments were reported across 109 transactions from 7 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($49,500).
Ad
Practice Information
- Specialty Addiction Medicine
- Other Specialties Psychiatry
- Location Lima, OH
- Active Since 10/10/2005
- Last Updated 11/27/2023
- Taxonomy Code 2084A0401X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1245228717
Products in Payments
- LYBALVI (Drug) $83,168
- Auvelity (Drug) $2,439
- INGREZZA (Drug) $412.54
- INVEGA SUSTENNA (Drug) $404.06
- ARISTADA (Drug) $342.21
- SPRAVATO (Drug) $211.18
- Aristada 441 mg (Drug) $186.17
- REXULTI (Drug) $137.27
- SUBLOCADE (Drug) $118.74
- ABILIFY MAINTENA (Drug) $114.11
- INVEGA TRINZA (Drug) $99.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.